The biochemical mechanisms underlying phagocytosis are still largely unknown. Two groups have previously determined that the glucose analogue 2-deoxyglucose (2DG) inhibits opsonin-dependent phagocytosis in a manner unrelated to energy production. We have recently described a cytoplasmic phosphoglycoprotein of 63 kDa (pgp 63) possessing an oligosaccharide that appears to exist in two interconvertible states, one as an O-linked mannose disaccharide and the other containing, in addition, a phosphodiester-linked glucose residue. We have also described the two antagonistic enzymes responsible for the removal and addition of the alphaGlc-1-P. Our data in other systems suggest that pgp63 may be intimately involved in the CA++-dependent cascade leading to exocytic vesicle release and that the removal and addition of alphaGlc-1-P is an integral part of this cascade. We intend to critically test the related hypotheses that a) the inhibitory effect of 2DG seen in opsonin-dependent phagocytosis is due to its conversion to UDP-2DG and the nucleotide sugar's subsequent effect on alphaGlc-1-P turnover on pgp63 and b) that pgp63 plays an important role in macrophage and neutrophil phagocytic function.
The specific aims of the proposal are: 1. To partially characterize the Glc phosphotransferase and its pgp63 acceptor in human neutrophils and mouse macrophages and to determine if a variety of treatments that modulate various aspects of neutrophil or macrophage function affect the levels of alphaGlc-1-P transfer to pgp63. 2. To determine if the inhibition of phagocytosis caused by 2DG can be attributed to its conversion to the 2-deoxy analogue of UDP-Glc, and also to determine if the beta-phosphorothioate analogue of UDP-Glc has similar inhibitory effects. 3. To determine the topographic distribution of pgp63 in macrophages at rest and as phagocytosis proceeds. 4. To determine if decrease in functional pgp63, induced by the introduction into the cytoplasm of either a monospecific antibody, phosphorothioate-containing pgp63, or a specific antisense oligonucleotide, affects phagocytic function in macrophages.

Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Wang, Hui; Rayburn, Elizabeth R; Wang, Wei et al. (2006) Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 5:2106-14
Annis, D S; Murphy-Ullrich, J E; Mosher, D F (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459-68

Showing the most recent 10 out of 145 publications